As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential best-in-class efficacy and convenience in gMG

U.S. regulatory application submitted; cemdisiran could be the first siRNA to be approved for the treatment of gMG

Regeneron to host virtual ‘Regeneron Roundtable: gMG & C5 Complement Program' investor event on Wednesday, April 22 at 8:30 a.m. ET

TARRYTOWN, N.Y., April 21, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced detailed positive results from the Phase 3 NIMBLE trial evaluating investigational cemdisiran in adults with generalized myasthenia gravis (gMG) were published in The Lancet and presented for the first time in an oral plenary session at the American Academy of Neurology (AAN) Annual Meeting. Cemdisiran is a novel siRNA therapeutic that durably reduces circulating levels of complement factor 5 (C5), allowing for every three months dosing.